Spots Global Cancer Trial Database for adc
Every month we try and update this database with for adc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | NCT06440005 | Cancer Advanced Cancer Locally Advance... Metastatic Soli... Triple Negative... Pancreas Cancer Pancreatic Aden... | AGX101 | 18 Years - | Angiex, Inc. | |
| DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | NCT03384940 | Colorectal Neop... | DS-8201a | 18 Years - | Daiichi Sankyo | |
| A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors | NCT05217693 | Solid Tumor | BB-1705 | 18 Years - 78 Years | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | |
| A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | NCT06005740 | Advanced Solid ... Hepatocellular ... | TORL-4-500 | 18 Years - | TORL Biotherapeutics, LLC | |
| A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors | NCT06241898 | Solid Tumor | BB-1709 | 18 Years - 78 Years | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | |
| A Study Of PF-06664178 In Patients With Advanced Solid Tumors | NCT02122146 | Neoplasms | PF-06664178 PF-06664178 | 18 Years - | Pfizer | |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | NCT02606305 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Mirvetuximab so... Bevacizumab Carboplatin Pegylated Lipos... Pembrolizumab | 18 Years - | ImmunoGen, Inc. | |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma | NCT06106945 | Multiple Myelom... | AZD0305 | 18 Years - | AstraZeneca | |
| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) | NCT05329545 | High Grade Sero... Fallopian Tube ... Primary Periton... | Upifitimab rils... Placebo | 18 Years - | Mersana Therapeutics | |
| Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | NCT04240704 | Non-Hodgkins Ly... Chronic Lymphoc... | JBH492 | 18 Years - | Novartis | |
| A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer | NCT06168227 | Breast Cancer | Disitamb Vedoti... | 18 Years - 85 Years | The First Affiliated Hospital with Nanjing Medical University | |
| A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors | NCT05217693 | Solid Tumor | BB-1705 | 18 Years - 78 Years | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | |
| Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy | NCT04319198 | Metastatic Soli... | Sacituzumab Gov... | 18 Years - | Gilead Sciences | |
| Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | NCT04925284 | Non Small Cell ... Cervical Cancer SCCHN Pancreatic Canc... Esophageal SCC Metastatic Cast... Triple Negative... Hormone Recepto... Epithelial Ovar... Endometrial Can... Tissue Factor-E... | XB002 Nivolumab | 18 Years - | Exelixis | |
| A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 | NCT05323045 | Solid Tumor | BYON3521 | 18 Years - | Byondis B.V. | |
| Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC) | NCT05837806 | Neoadjuvant Imm... | tislelizumab+di... | 18 Years - | Tianjin Medical University Second Hospital | |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) | NCT05445778 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Mirvetuximab so... Bevacizumab | 18 Years - | ImmunoGen, Inc. | |
| A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer | NCT01237678 | Small Cell Lung... | IMGN901 Carboplatin and... | 18 Years - | ImmunoGen, Inc. | |
| Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | NCT03366428 | Malignant Neopl... | DS-8201a | 20 Years - | Daiichi Sankyo | |
| A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 | NCT04202705 | Solid Tumor | SYD1875 | 18 Years - | Byondis B.V. | |
| A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | NCT06005740 | Advanced Solid ... Hepatocellular ... | TORL-4-500 | 18 Years - | TORL Biotherapeutics, LLC | |
| A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | NCT02222922 | Neoplasms | PF-06647020 Q3W fluconazole PF-06647020 Q2W PF-06647020 com... | 18 Years - | Pfizer | |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC | NCT05979740 | Muscle Invasive... HER2 Expression Radiotherapy PD-1 Antibody-drug C... | Disitamab Vedot... | 18 Years - | RenJi Hospital | |
| A Study Of PF-06647263 In Patients With Advanced Solid Tumors | NCT02078752 | Neoplasms Triple-Negative... | PF-06647263 PF-06647263 | 18 Years - | Pfizer | |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC | NCT05979740 | Muscle Invasive... HER2 Expression Radiotherapy PD-1 Antibody-drug C... | Disitamab Vedot... | 18 Years - | RenJi Hospital | |
| Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer | NCT01591590 | Colorectal Canc... | FDG PET-CT Diffusion MRI Blood samples (... | 18 Years - | Jules Bordet Institute | |
| A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | NCT02512237 | Breast Neoplasm... Stomach Neoplas... | ARX788 | 18 Years - | Zhejiang Medicine Co., Ltd. | |
| A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | NCT02222922 | Neoplasms | PF-06647020 Q3W fluconazole PF-06647020 Q2W PF-06647020 com... | 18 Years - | Pfizer | |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC | NCT05979740 | Muscle Invasive... HER2 Expression Radiotherapy PD-1 Antibody-drug C... | Disitamab Vedot... | 18 Years - | RenJi Hospital | |
| Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer | NCT04940325 | Metastatic Lung... | DS-1062a | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| The Rechallenge of ADCs in MBC Patients | NCT05571618 | Breast Cancer | ADC | 18 Years - | Fudan University | |
| Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | NCT04240704 | Non-Hodgkins Ly... Chronic Lymphoc... | JBH492 | 18 Years - | Novartis | |
| A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | NCT06005740 | Advanced Solid ... Hepatocellular ... | TORL-4-500 | 18 Years - | TORL Biotherapeutics, LLC | |
| DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | NCT03384940 | Colorectal Neop... | DS-8201a | 18 Years - | Daiichi Sankyo | |
| Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer | NCT01591590 | Colorectal Canc... | FDG PET-CT Diffusion MRI Blood samples (... | 18 Years - | Jules Bordet Institute | |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | NCT05104866 | Breast Cancer | Dato-DXd Capecitabine Gemcitabine Eribulin Vinorelbine | 18 Years - | AstraZeneca | |
| Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | NCT03366428 | Malignant Neopl... | DS-8201a | 20 Years - | Daiichi Sankyo | |
| Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors | NCT04235101 | Solid Tumor | SYD985 + Nirapa... | 18 Years - | Byondis B.V. | |
| A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | NCT05629585 | Breast Cancer | Dato-DXd Durvalumab Capecitabine Pembrolizumab | 18 Years - 130 Years | AstraZeneca | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| A Study of KM501 in Patients With Solid Tumors | NCT05804864 | Advanced Solid ... | KM501 | 18 Years - 75 Years | Xuanzhu Biopharmaceutical Co., Ltd. | |
| ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer | NCT04662580 | Prostate Cancer | ARX517 | 18 Years - | Ambrx, Inc. | |
| Study of DS-8201a for Participants With Advanced Solid Malignant Tumors | NCT03383692 | Neoplasm Metast... | DS-8201a Ritonavir Itraconazole | 20 Years - | Daiichi Sankyo | |
| A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT05613088 | Neoplasms, Ovar... | MORAb-202 Paclitaxel Pegylated Lipos... Topotecan | 18 Years - | Bristol-Myers Squibb | |
| FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC | NCT06303505 | Ovarian Cancer Non-small Cell ... | TUB-040 | 18 Years - | Tubulis GmbH | |
| Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis | NCT04132960 | Breast Tumors | DS-8201a | 18 Years - | UNICANCER | |
| A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | NCT02512237 | Breast Neoplasm... Stomach Neoplas... | ARX788 | 18 Years - | Zhejiang Medicine Co., Ltd. | |
| A Phase 1/2 Study of PBI-410 in Advanced Solid Tumors | NCT06384807 | Solid Tumor | PBI-410 | 18 Years - | Pyramid Biosciences | |
| Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma | NCT01827709 | Head and Neck C... | A polymerase ch... Functional imag... Immunohistochem... MRI of the rese... Tumour volume d... | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | NCT04240704 | Non-Hodgkins Ly... Chronic Lymphoc... | JBH492 | 18 Years - | Novartis | |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer | NCT04965766 | Metastatic Brea... | U3-1402 | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | NCT02222922 | Neoplasms | PF-06647020 Q3W fluconazole PF-06647020 Q2W PF-06647020 com... | 18 Years - | Pfizer | |
| HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | NCT02947152 | Epithelial Ovar... Renal Cell Carc... | HKT288 | 18 Years - | Novartis | |
| Prediction of Outcome After Chemoradiotherapy for Head and Neck Cancer Using Functional Imaging and Tumor Biology | NCT01829646 | Head and Neck C... | functional MRI Hypoxia gene ex... Functional MRI ... | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors | NCT04235101 | Solid Tumor | SYD985 + Nirapa... | 18 Years - | Byondis B.V. | |
| FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC | NCT06303505 | Ovarian Cancer Non-small Cell ... | TUB-040 | 18 Years - | Tubulis GmbH | |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | NCT02631876 | Epithelial Ovar... Primary Periton... Fallopian Tube ... Ovarian Cancer | Mirvetuximab so... Paclitaxel Pegylated lipos... Topotecan | 18 Years - | ImmunoGen, Inc. | |
| Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors | NCT05797168 | Ovarian Cancer Lung Adenocarci... | AZD5335 AZD5305 | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
